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Abstract Nuclear hormone receptors are transcription factors
regulated by lipophilic ligands. These hormones bind to their
nuclear receptor targets using an induced fit mechanism that
triggers a large conformational change and generates the proper
surface for the binding of protein coactivators. The molecular
details of the various steps of this activation process or its
inhibition by antagonists are now understood for several nuclear
receptors. ß 2000 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Lipophilic hormones including retinoids, steroids, vitamin
D3, thyroxine and eicosanoids are potent regulators of devel-
opment, cell division and di¡erentiation, organ physiology,
metabolism and homeostasis. The pleiotropic e¡ects of these
hormones are mediated through speci¢c intracellular proteins
belonging to the nuclear receptor (NR) superfamily [1], whose
principal target is in the nucleus. These ligand-inducible tran-
scription factors are represented throughout the animal king-
dom in vertebrates, arthropods and nematodes. All the mem-
bers of this superfamily share a common functional and
structural architecture consisting of six domains [2] with a
variable A/B amino-terminal region, a highly conserved C
domain (V70^80 amino acids) responsible for speci¢c DNA
binding of the receptor to its target DNA sequence and weak
dimerization, a £exible linker D region and the moderately
conserved carboxy-terminal E domain (V250 amino acids)
named the ligand binding domain (LBD) responsible for hor-
mone binding and strong dimerization [3]. The two distinct
autonomous activation transactivation functions AF-1 and
AF-2 are carried by the A/B and E regions, respectively. In
contrast to the constitutively active function AF-1, AF-2 is a
ligand-dependent function which is critical for the regulation
of transcription [4]. Physiologically, NRs can be active molec-
ular entities in monomeric, homodimeric or heterodimeric as-
sociation states [5,6].
2. Ligand-induced conformational changes
2.1. Three major conformational states of NR LBDs
The crystal structures of several LBDs of di¡erent nuclear
receptors have been solved: RXR (retinoid X receptor) [7,8],
RAR (retinoic acid receptor) [9,10]; TR (thyroid receptor)
[11], PPAR (peroxisome proliferator-activated receptor) [12^
14]; ER (estrogen receptor) [15^17], PR (progesterone recep-
tor) [18,19], and VDR (vitamin D3 receptor) [20]. The two
recently reported structures of NR LBD heterodimers in the
case of RXR/RAR [21] and RXR/PPAR [22] make it possible
to establish the structural basis of allosteric interactions be-
tween subunits within such NR LBD heterodimers. Taken
together, all these structures con¢rmed the existence of a com-
mon fold [23] encompassing 12 K-helices (numbered H1^H12)
and a L-turn, arranged as a three-layered antiparallel K-helical
‘sandwich’ (Fig. 1). These structures also point to the fact that
major structural changes occur upon ligand binding [3,24,25].
The existence of a large conformational di¡erence between an
‘open’ apo-form and a compact ‘closed’ holo-form was ¢rst
illustrated by the comparison between the two X-ray struc-
tures of apo-RXRK [7] and holo-RARQ bound to all-trans
retinoic acid (AT-RA) [9]. Furthermore, comparison of ago-
nist- versus antagonist-bound LBDs structures revealed the
existence of two distinct conformations for the C-terminal
transactivation helix H12 positioned in two conserved hydro-
phobic grooves (therefore called agonist and antagonist
grooves) displayed at the NR LBD surfaces (Fig. 1). These
crystallographic studies strongly support the concept of the
uniqueness of the holo-agonist conformation among all NR
LBDs versus more variable conformations of the other func-
tional states.
2.2. The coregulator binding sites
Several proteins interacting with NRs have been identi¢ed.
These include some general transcription factors such as
TFIIB and some TAFs (TATA-box binding protein-associ-
ated factors). The transcription regulation involves the recruit-
ment of coactivators and corepressors and hormonal-depen-
dent remodelling of chromatin via a subtle balance in the
acetylation/deacetylation level of the histone components of
nucleosomes triggered by acetylation or deacetylation enzy-
matic machineries [26^28]. Some corepressors have been iden-
ti¢ed that interact with apo-receptors and are released upon
ligand/agonist binding [29,30]. For coactivators, the so-called
TIFs (transcriptionally intermediary factors) act as trans-
ducers between the NR AF-2s and the basal transcriptional
machinery; they interact with NR LBDs in a ligand/agonist-
and AF-2 integrity-dependent manner. From the available
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crystal structures, it is inferred that NR LBDs are signal-re-
sponsive regulatory modules adopting distinct conformations
as apo-receptors, holo-agonist-bound or holo-antagonist-
bound species (Fig. 1) supporting or precluding interactions
with proteins such as chaperones, coactivators [31^33] or
corepressors [34^36]. The NR interacting domains of coacti-
vators and corepressors have been analyzed and consensus
sequences of type LXXLL (L: leucine, X: any amino acid)
have been identi¢ed. Interestingly, LXXLL-like motifs are
also present in the amphipathic helix H12 of NRs
[13,16,31,33] and in the NR interacting domains (ID1, 2) of
corepressors [34^36]. The crystal structures of three agonist
complexes of NR LBDs, namely ERK [16], TRL [37] and
PPARQ [13] bound to LXXLL peptides, revealed that such
peptides adopt a helical conformation and occupy the so-
called antagonist groove, whereas the agonist groove is occu-
pied by helix H12. The crystal structure of the RXR/RAR
heterodimer bound to oleic acid and the RAR selective antag-
onist BMS614 also make it possible to visualize both LBDs in
their antagonistic conformations [21] (see Fig. 1). This struc-
tural evidence indicates (i) the possibility of a competition
mechanism in the occupancy of either agonist and antagonist
surfaces by either corepressor or coactivator NR interacting
domains (H12 in the ‘antagonist’ conformation mimics the
coactivator NR box peptide (Fig. 1)), and (ii) the high degree
of dynamic and conformational variability of the transactiva-
tion helix H12, a critical substructure in signal transduction
by NRs. The ligand-induced transconformation of H12 to-
gether with the associated structural changes a¡ecting mainly
helices H3, H6 and H11 are crucial for the generation of
transcriptionally active receptors; it generates a subset of sur-
faces that allow subsequent speci¢c binding of coactivators
and disrupt the interaction surfaces with corepressors.
2.3. Ligand binding mechanism: the RXR model
The existence of a conformational change between an
‘open’ apo-form and a compact ‘closed’ holo-form has been
recently highlighted by the direct comparison between the two
X-ray structures of apo-RXRK [7] and holo-RXRK bound to
9-cis retinoic acid (9C-RA) [8] showing the same receptor in
its two extreme conformational states (Fig. 2). A similar con-
formation has been observed in the heterodimer RXR/PPAR
bound to 9C-RA and rosiglitazone, respectively [22]. The apo-
form exhibits an additional helix (H2) in the region connect-
ing helix H1 and helix H3. In the holo-form, this segment
unfolds and the £exible loop region sticks to the protein.
This di¡erent conformation of loop H1^H3 probably illus-
trates the dynamics of this region that may act as a molecular
spring accompanying the movement of helix H3 which under-
goes a very large conformational change. Among the numer-
ous NR LBD crystal structures solved, it has also been re-
Fig. 1. The three conformational states of the nuclear receptor LBDs known so far: apo-form (left), holo-agonist (middle) and holo-antagonist
(right) states, represented by apo-RXRK [7], RXRK/9C-RA [8] (model with SRC1 coactivator peptide from PPAR [13]) and RARK/BMS614
[21] (subunit of the RXRK heterodimer). Note the di¡erent positions of helix H12 (colored in black). In the antagonist position, H12 occupies
precisely the position of the coactivator ^ the molecular basis of nuclear receptor antagonism.
Fig. 2. Ligand-induced conformational changes in RXRK LBD.
Superposition of apo-RXRK (in light gray) and holo-RXRK/9C-RA
(in dark gray) LBD structures. The arrows emphasize the main
structural changes a¡ecting helices H3, H6, H11 and transactivation
helix H12. For the sake of clarity the ligand has not been drawn.
In the apo-form solvent-exposed phenylalanine residues are colored
in black whereas the buried phenylalanine is drawn in light gray; in
the holo-form the respective solvent accessibilities of these residues
are inverted.
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ported that this H1^H3 connecting region is often poorly
ordered and shows little if any secondary structure. The N-
terminal part of H3 rotates by about 90‡ around its helical
axis and packs against the ligand binding pocket. This H3
movement, which is permitted by the displacement of helix
H11 from its apo-position, is concomitant with the binding
of the ligand in an induced ¢t mechanism. The conformation-
al change brings essential residues into contact with the li-
gand, seals the binding pocket and generates the proper
H12 binding surface.
While helix H11 is kinked in the RXRK apo-LBD thereby
¢lling the unoccupied binding pocket, in the RXRK holo-LBD
it adopts a regular K-helical conformation in the continuity of
H10. In the absence of the ligand, H11 stabilizes the apo-form
by ¢lling the pocket with several hydrophobic residues (Leu-
441, Phe-437 and Phe-438) while two other hydrophobic side
chains from the same helix (Leu-436 and Phe-439) are exposed
to the solvent. In the holo-form, H11 (displaced by helix H3)
moves away and rotates by 180‡ around its own axis, gener-
ating a proper ligand binding site and helping the reposition-
ing of helix H12. In the RXRK holo-LBD, 9C-RA occupies
the binding pocket and the side chains of Leu-441, Phe-437
and Phe-438 are exposed to the solvent, while the side chains
of Leu-436 and Phe-439 are internalized and form the lower
part of the binding pocket. In conclusion, H11 exposes one
face toward the solvent in the apo-state (presumably the core-
pressor interacting interface) and the other face in the holo-
state. These movements of helix H11 emphasize the role of
solvation versus desolvation processes in the structural tran-
sition. Such entropic e¡ects are expected to be general to
other NR LBDs.
The most striking conformational change a¡ects helix H12
(Fig. 2) which is completely repositioned upon ligand binding:
in the apo-form, H12 protrudes from the protein core and is
exposed to the solvent, whereas in the holo-form it rotates and
folds back toward the ligand binding pocket, thus inducing
the compaction of the LBD. As a result, some key residues of
the AF-2 AD core become exposed to the solvent and are
available for interaction with coactivators mediating tran-
scriptional activation. In summary, ligand binding, acting ¢rst
through the rearrangement of helix H3, induces the reposi-
tioning of helix H12 by expelling helix H11.
3. Speci¢city of ligand recognition
NR ligands generally exhibit strong a⁄nities for their tar-
gets (dissociation constants are in the nanomolar to micro-
molar range) which is associated with a high speci¢city. Li-
gand speci¢city is crucial from the point of view of both
cellular transcription regulation and therapeutic applications.
Considering the chemical similarity of natural ligands as es-
tradiol and progesterone, or AT-RA and 9C-RA ^ the bio-
logically active metabolites of vitamin A (Fig. 3A,B) ^ Nature
has generated an astonishing potential for discriminating be-
tween these pairs. In the following, we discuss both examples.
According to the phylogenetic analysis of their sequences,
RXR, RAR, ER and PR belong to di¡erent subgroups of
nuclear receptors. RAR and RXR LBDs have only modest
sequence identity (30%), which is only slightly higher than
that observed between the ER and PR LBDs (23%), whereas
ER and RXR LBDs share 27% of their sequence [23]. There-
fore, it is intriguing that estradiol and progesterone bind to
distinct receptors, whereas 9C-RA binds to both RXR and
RAR.
3.1. Estradiol versus progesterone
The crystal structures of estradiol bound to ER and pro-
gesterone bound to PR [15,18,19] illustrate how receptor-spe-
ci¢c residues provide selective interactions with the ligand
(Fig. 3A): the hydroxyl groups of estradiol act as hydrogen
bond donors, whereas the ketone groups of progesterone act
as hydrogen bond acceptors. Accordingly, in the vicinity of
the 3-hydroxyl/3-keto groups, a key residue is converted from
a hydrogen bond acceptor (Glu-353 of ERK) into a hydrogen
bond acceptor (Gln-725 in PR) which optimizes the hydrogen
bond pattern with one/two water molecules and the arginine
and phenylalanine residues (Arg-394/Phe-404 in ERK, Arg-
766/Phe-778 in PR). The arginine residue is conserved in the
steroid receptor family, as well as in RAR (Arg-278) and
RXR (Arg-316) where it is hydrogen-bonded to the carbox-
ylate group of the ligand (Fig. 3C).
3.2. Ligand adaptability: AT-RA versus 9C-RA
Whereas RXR exclusively binds 9C-RA, RAR binds both
AT-RA and 9C-RA stereoisomers [38,39]. The comparison of
the crystal structures of AT-RA and 9C-RA bound to RARQ
[9,10] addresses the question of recognition of di¡erent ligands
by the same environment, i.e. the same receptor. Although the
isomers of retinoic acid appear to have di¡erent shapes in the
free state, the ligands turned out to be very similar once
bound (Fig. 3B), as their intrinsic £exibility allows them to
¢t into a structurally unique ligand binding pocket [10]. The
conformational adaptation to the cavity leads to an identical
protein conformation. In particular, the agonist position of
helix H12 is conserved (Fig. 1) and accounts for the similar
binding and activation properties of AT-RA and 9C-RA.
3.3. 9C-RA bound to RXR or RAR
The £exibility of 9C-RA allows it to adopt di¡erent con-
formations in RAR and RXR (Fig. 3B), as revealed by the
crystal structures of the respective LBD complexes [8,10]. In
RXR, 9C-RA exhibits a pronounced bend, whereas in RAR
its shape is closer to that observed for AT-RA bound by
RAR. The geometry of the RXRK ligand binding pocket se-
lects the 9-cis isomer but excludes the all-trans isomer due to
its £exure limit [10]. The lower a⁄nity of RXRK for 9C-RA
(Kd = 2 nM) compared to RARQ (Kd = 0.2^0.8 nM for AT-RA
and 9C-RA) [40,41] could be explained by a smaller number
of hydrophobic contacts which re£ects the lower occupancy of
the cavity in RXRK compared to that of RARQ.
Due to a di¡erent orientation and location of the L-ionone
binding sites in RAR and RXR, the L-ionone ring of 9C-RA
exhibits a rotation of about 90‡ (Fig. 3B). Therefore, in RXR
it points to the bottom of the LBD (away from helix H12),
whereas in RAR it makes hydrophobic contacts with helix
H12. The ligand shift towards the center of the RXR cavity
is accompanied by a shift of the side chain of the conserved
Arg-316 (Arg-278 in RARQ, Fig. 3C) in order to maintain its
interaction with the carboxylate group of 9C-RA.
3.4. NR isotypes as distinct pharmaceutical targets
The existence of receptor isotypes (e.g. ERK and L, LBD
sequence identity 59%; RARK, L and Q, LBD sequence iden-
tity s 80%) raises the question of speci¢c ligand recognition
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achieved with ligand binding cavities that are highly conserved
within a receptor subfamily. Moreover, speci¢city for a given
isotype is of considerable importance for therapeutic applica-
tions. ER is a target for chemotherapeutic drugs against cer-
tain reproductive cancers, in particular breast cancer. Ligands
like the agonist estradiol, the partial antagonist raloxifen or
the phytoestrogen genistein (an ERL-selective partial agonist)
exhibit di¡erent pharmacological pro¢les with respect to the
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ERK, L isotypes [42] as illustrated by the crystal structures of
the ERK and ERL LBDs bound to several of these ligands
[15,17,39]. Two residues in the ERK, L pockets that are not
conserved are presumably responsible for ER isotype selectiv-
ity.
Retinoids are involved in the treatment of various skin dis-
eases and cancers, in particular breast cancer and acute pro-
myelocytic leukemia [43^45]. Since the RARK, L and Q iso-
types [46] correspond to distinct pharmacological targets,
retinoids selective for the individual isotypes are required. Se-
quence alignment of the RAR isotypes shows that all but
three residues in the ligand binding pocket are conserved
[9,10,23] (Fig. 3C), and their crucial role for isotype selectivity
has been demonstrated by site-directed mutagenesis [47].
3.5. RAR isotype selectivity
Several crystal structures of complexes of the hRARQ LBD
bound to chemically closely related agonist retinoids have
been reported recently [48,49]. They illustrate how synthetic
retinoids achieve isotype selectivity, whereas the natural li-
gands behave as panagonists (Fig. 3C): for example, the
RARQ-selective BMS184394 carries a hydroxyl group in the
bridge connecting the two aromatic rings, whereas the
RARL,Q-selective CD564 has a keto moiety at that position
(Fig. 3C). The hydroxyl group provides an additional hydro-
gen bond with the sulfur atom of the RARQ-speci¢c Met-272
that is replaced by isoleucine residues in RARK and L. In
contrast, the keto group of CD564 disrupts the hydrogen
bond observed in the BMS184394 complex as illustrated by
the di¡erent conformation of the Met-272 side chain, resulting
in a shift from RARQ to RARL,Q selectivity (Fig. 3C). In the
same way, the isoleucine residues in RARK and L that corre-
spond to Met-272 allow CD564 to bind but disrupt the hydro-
gen bond with RARQ-selective ligands. The molecular basis
for RARQ selectivity appears to be unique, since the hydrogen
bond with Met-272 is a common feature of all crystal struc-
tures of complexes with RARQ-selective ligands solved so far
[48,49]. It is important to note that the correct orientation of
the hydroxyl group is a prerequisite for RARQ selectivity and
a⁄nity since RAR turned out to exhibit a strong enantiomer
selectivity. Inactive enantiomers may bind at high ligand con-
centrations but adopt energetically unfavorable conformations
and exhibit close contacts with residues in the pocket [48]. In
contrast to the just discussed introduction of speci¢c ligand^
protein interactions, RARK discrimination is probably based
on steric contact between the ligand (CD564 for example)
with the RARK-speci¢c serine residue that replaces Ala-234
(RARQ, Fig. 3C), whereas panagonists (including AT-RA and
9C-RA) are smaller in this region and more £exible which
allows accommodation to any of the RAR isotypes [49].
This is also suggested by the orientation of the serine side
chain observed in an RARK LBD ligand complex [21], and
corroborated by the small size of RARK-selective retinoids.
4. Concluding remarks
Over the last years joined e¡orts from di¡erent disciplines
have provided insight into the regulation of gene activity by
nuclear receptors. Numerous ligands have been synthesized
for therapeutic applications, with the aim of being more iso-
type-speci¢c and with fewer side e¡ects for therapeutic appli-
cations. However, until recently their chemical structure and
activation properties could not be correlated with the struc-
ture of their target. The increasing number of crystallographic
data on ligand complexes may contribute to the structure-
based drug design of new, in particular isotype-selective li-
gands. For example, the high resolution crystal structures of
speci¢c complexes revealed that £exible ‘second layer residues’
represent a second level of adaptation mediating di¡erent con-
formations of residues in close contact with the ligand (e.g.
Met-272 in RARQ, see Fig. 3C). In the RXR pocket all resi-
dues are conserved whereas the second layer residues are not
[8]. Considering combined adaptations of ¢rst and second
layer residues may be the key for the design of RXR iso-
type-selective retinoids that are missing up to now.
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